Pembrolizumab (new indication: breast cancer, triple-negative, PD-L1 expression ≥ 10 (CPS), in combination with chemotherapy)


  • Active Substance: Pembrolizumab
  • Name: Keytruda®
  • Therapeutic area: Breast cancer
  • Pharmaceutical company: MSD Sharp & Dohme GmbH

Time table:

  • Start: 15.11.2021
  • Final decision by G-BA: 05.05.2022

Final decision:

  • Pembrolizumab in combination with nab-paclitaxel or paclitaxel in comparison to nab-paclitaxel or paclitaxel: Hint for a considerable additional benefit
  • Pembrolizumab in combination with a chemotherapy except for nab-paclitaxel or paclitaxel: No additional benefit proved